PIPE-307 demonstrated an acceptable safety and tolerability profile PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter acuity (LCLA) SAN DIEGO / Nov 20, 2025 / Business Wire / Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or...Read more
CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,...Read more
Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable...Read more
FDA Response Streamlines Path to Commercial Production of PF614 SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system...Read more
Following Priority Review, the U.S. FDA granted HYRNUO® (sevabertinib) approval for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by...Read more
EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...Read more
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Regeneron Pharmaceuticals | 34.25 4.87 | $737.00 |
| Nutex Health | 30.15 26.87 | $142.34 |
| Exact Sciences | 14.44 16.76 | $100.62 |
| Abivax | 9.95 8.81 | $122.90 |
| PACS Group | 9.05 53.77 | $25.88 |
| Natera | 7.20 3.30 | $225.55 |
| Movano Health | 6.97 224.12 | $10.08 |
| Tyra Biosciences | 4.38 26.35 | $21.00 |
| Bolt Biotherapeutics | 4.24 758.68 | $4.80 |
| argenx | 3.91 0.43 | $918.50 |
| Olema Oncology | 2.58 13.28 | $22.01 |
| GE HealthCare | 2.44 3.37 | $74.75 |
| iRhythm Technologies | 2.40 1.43 | $169.70 |
| Waters | 2.37 0.63 | $378.62 |
| STERIS | 2.27 0.89 | $256.98 |
| UnitedHealth | 2.24 0.72 | $311.33 |
| Agios Pharmaceuticals | 2.23 9.98 | $24.57 |
| Solventum | 2.20 2.85 | $79.51 |
| Company | Volume | Last Trade |
|---|---|---|
| Mobile-health Network Solutions | 239,422,396 | $3.11 |
| Exact Sciences | 135,685,393 | $100.62 |
| Psyence Biomedical | 75,110,068 | $1.73 |
| Plus Therapeutics | 72,472,636 | $0.49 |
| Recursion | 59,508,228 | $3.85 |
| Applied Therapeutics | 53,404,804 | $0.28 |
| Pfizer | 50,550,442 | $24.40 |
| PacBio | 36,706,412 | $1.89 |
| Geron | 34,383,951 | $1.10 |
| Clearmind Medicine | 31,135,451 | $0.20 |
| Heron Therapeutics | 29,635,469 | $1.06 |
| InMed Pharmaceuticals | 29,121,524 | $1.24 |
| Olema Oncology | 27,044,195 | $22.01 |
| Humacyte | 26,515,071 | $1.12 |
| Moderna | 25,146,897 | $22.36 |
| ImmunityBio | 21,468,334 | $2.02 |
| Agios Pharmaceuticals | 20,961,226 | $24.57 |
| Nuvation Bio | 20,136,659 | $7.02 |
| Incannex Healthcare | 19,075,044 | $0.33 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
